The Latest Cardiac and Vascular News
Trial completion marks an important milestone in the development of the next generation, embolic protection platform MINNEAPOLIS, Nov. 21, 2024 /PRNewswire/ — Cardiovascular medical device company, EmStop, Inc., today announced the completion of the CAPTURE-1 early feasibility clinical…
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. STEM is the first randomized prospective IDE trial investigating embolization of the MMA for the treatment of cSDH.
SEISMIC-HF I enrolled a large, demographically diverse population across 15 sites Results are an important step toward enabling widespread, non-invasive hemodynamic-guided heart failure management CHICAGO, Nov. 20, 2024 /PRNewswire/ — Cardiosense, a medical AI company transforming the…
Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies Medtronic plc, a global leader in healthcare technology, today announced it began a randomized study sponsored by Tempus, a technology company leading the adoption […]
Akumin Introduces AXIS – Reimagining How Radiology and Oncology Services Are Delivered PLANTATION, FL, Nov. 20, 2024 /PRNewswire/ – Akumin, a leader in managed radiology and oncology services, is proud to launch Akumin AXIS Expandable Patient Solutions™ at RSNA 2024. The Akumin AXIS unit…
EchoGo® Amyloidosis is an AI-based software-only medical device, which aims to improve early detection of Cardiac Amyloidosis, an underdiagnosed cause of heart failure. EchoGo® Amyloidosis sits on Ultromics’ EchoGo® platform complementing the existing commercialized EchoGo® Heart Failure…
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
Nov 19, 2024 Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time – Click Here to Access IRVINE, CA / November 19, […]
he studies further strengthen HeartBeam’s body of clinical evidence for its portable, cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG The first study is a pilot study demonstrating similar performance of HeartBeam’s vector-based ambulatory technology to standard 12-lead ECGs for arrhythmia detection The […]
